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Abstract
Background: Work problems are common in people with inflammatory arthritis. Up to 50% stop work within 10
years due to their condition and up to 67% report presenteeism (i.e. reduced work productivity), even
amongst those with low disease activity. Job retention vocational rehabilitation (JRVR) may help prevent or
postpone job loss and reduce presenteeism through work assessment, work-related rehabilitation and enabling job
accommodations. This aims to create a better match between the person’s abilities and their job demands. The
objectives of the Workwell trial are to test the overall effectiveness and cost-effectiveness of JRVR (WORKWELL)
provided by additionally trained National Health Service (NHS) occupational therapists compared to a control group
who receive self-help information both in addition to usual care.
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Methods: Based on the learning from a feasibility trial (the WORK-IA trial: ISRCTN76777720), the WORKWELL trial is a
multi-centre, pragmatic, individually-randomised parallel group superiority trial, including economic evaluation,
contextual factors analysis and process evaluation. Two hundred forty employed adults with rheumatoid arthritis,
undifferentiated inflammatory arthritis or psoriatic arthritis (in secondary care), aged 18 years or older with work
instability will be randomised to one of two groups: a self-help written work advice pack plus usual care (control
intervention); or WORKWELL JRVR plus a self-help written work advice pack and usual care. WORKWELL will be
delivered by occupational therapists provided with additional JRVR training from the research team. The primary
outcome is presenteeism as measured using the Work Limitations Questionnaire-25. A comprehensive range of
secondary outcomes of work, health, contextual factors and health resource use are included. Outcomes are
measured at 6- and 12- months (with 12-months as the primary end-point). A multi-perspective within-trial cost-
effectiveness analyses will also be conducted.
Discussion: This trial will contribute to the evidence base for provision of JRVR to people with inflammatory
arthritis. If JRVR is found to be effective in enabling people to keep working, the findings will support decision-
making about provision of JRVR by rheumatology teams, therapy services and healthcare commissioners, and
providing evidence of the effectiveness of JRVR and the economic impact of its implementation.
Trial registration: Clinical Trials.Gov: NCT03942783. Registered 08/05/2019 (https://clinicaltrials.gov/ct2/show/NCT03
942783); ISRCTN Registry: ISRCTN61762297. Registered:13/05/2019 (http://www.isrctn.com/ISRCTN61762297).
Retrospectively registered.
Keywords: Arthritis, Vocational rehabilitation, Occupational therapy, Presenteeism, Absenteeism, Randomised
controlled trial
Background
Fifty per cent of people with rheumatoid arthritis (RA)
stop working due to their condition (i.e. are work dis-
abled) within 10 years of diagnosis [1]. Work disability
seems to be reducing, possibly due to earlier aggressive
drug treatment [2]. However, presenteeism (i.e. reduced
work productivity) is still reported by 67%, even with
low disease activity [3]. Alongside the broader economic
impact of work limitations due to arthritis, the effect on
individuals’ quality-of-life has also been acknowledged
[4]. Job retention vocational rehabilitation (JRVR) can
potentially prevent or postpone work disability and re-
duce presenteeism through structured work assessment,
work-related rehabilitation and modifying work to suit
the person’s condition and ability (termed job accommo-
dations) and creating a better match between the per-
son’s abilities and their job demands [5].
JRVR provision varies between countries. In the
United Kingdom (UK), many with RA, early or undiffer-
entiated inflammatory arthritis (UIA) and psoriatic arth-
ritis (PsA) lack access to JRVR. In the UK National
Health Service (NHS), work-related support in many
Rheumatology services are either non-existent or patchy.
Where this exists, it is usually provided in occupational
therapy to only a few patients per month, often when
patients are referred for other reasons. Brief work advice
lasts on average 45 min, without a structured work as-
sessment, and includes signposting to work services,
providing information booklets and self-management
education related to work, e.g. fatigue management, joint
protection, pacing, as well as splinting) [6, 7]. In the
workplace, access to occupational health is common
only in larger organisations. There is some UK
Government-funded support, such as the Access to
Work (AtW) scheme, providing advice and grants for
job accommodations [8] but there is low awareness of
this amongst employees with arthritis and employers [9].
Disability Employment Advisors (working in Job
Centres) usually provide advice to those already un-
employed. Additionally, Fit for Work is an online re-
source, with an individual telephone advice service, to
supplement the occupational health advice that em-
ployers may provide [10]. In Western Europe, work re-
habilitation is provided by, for example: local authorities
funded through the social service system (Denmark)
[11]; local social insurance offices directly providing or
funding services from work rehabilitation providers
(Sweden) [12]; statutory pension insurance funded re-
habilitation centres (Germany) [13]; and occupational
physicians collaborating with health professionals, as all
companies legally must have a contract with occupa-
tional health services (the Netherlands) [14]. In the
United States, VR is provided by VR counsellors through
federal-funded VR State Agencies [15].
There is limited evidence for effectiveness of JRVR in
employed people with RA, UIA and PsA. A systematic
review of randomised controlled trials (RCTs: with more
than 50% participants with RA, UIA or PsA) identified
two trials with positive results and one with no effects
[5]. A small UK trial of occupational therapy (OT) and
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JRVR resulted in reduced work instability and improved
self-reported ability to manage at work, at 6 months
[16]. A brief JRVR intervention in the United States of
America (USA) led, to reduced job loss at 4 years [17].
An RCT of a multidisciplinary JRVR programme in the
Netherlands identified no changes in work outcomes,
However, 40% of participants were already on long-term
sick leave, suggesting the intervention may have been
too late for many [14]. We systematically searched Med-
line, Cumulative Index of Nursing and Allied Health Lit-
erature and PubMed from 1980 to end 2018 for JRVR
trials either published since the Hoving et al. [5] review
or with less than a 50% sample with RA, UIA or PsA. A
further trial of multidisciplinary JRVR, including an OT-
led work site visit and employer liaison, also led to no
changes in work outcomes in the Netherlands. Many
participants had low scores on the RA-Work Instability
Scale, indicating few work problems, suggesting the
intervention may have been too early [18]. Two further
RCTs in the USA identified positive outcomes at two-
year follow-up. An OT-led workplace ergonomic inter-
vention (38% RA) resulted in significant improvement in
self-reported work impairment but not pain, job satisfac-
tion, physical function or mood [19]. A brief JRVR inter-
vention provided by OTs and physiotherapists (PTs)
(33% IA), based on the Allaire et al. [17] trial, led to re-
duced job loss but not presenteeism [20, 21].
Differing economic, social security and health services
between countries mean it is difficult to extrapolate
whether positive results for JRVR in one country trans-
late to another. The review indicated brief JRVR, based
on those in the USA [17, 21], delivered by OTs and PTs
given additional JRVR training, as part of Rheumatology
health services, could be effective in the UK. Cost-
effectiveness was not evaluated in these trials. Consider-
ing finite available resources, decision-makers in health
and other sectors will also require information about the
value-for-money that JRVR provides. Economic evalu-
ation is a formal process which facilitates the synthesis
of an intervention’s costs and outcomes to provide esti-
mates of its cost-effectiveness.
Feasibility study
We conducted a feasibility study, the WORK-IA trial, of
JRVR for employed people with RA, UIA and PsA. In
this, we: developed a JRVR training programme for OTs,
effective in increasing OTs knowledge of and confidence
in delivering JRVR [6]. We also modified and further de-
veloped for the UK the: Work Environment Survey for
Rheumatic Conditions (WES-RC) [22, 23]; the WES-RC
Manual [24]; and the brief JRVR intervention developed
by Allaire et al. [17, 25]. We developed a Workwell Solu-
tions Manual of work resources and solutions for thera-
pists, linked to the WES-RC. We then conducted an
RCT (n = 55), comparing a control intervention (written
self-help work advice and usual care) to JRVR plus writ-
ten self-help work advice and usual care. The results of
this study indicated that therapists could successfully de-
liver JRVR, participants considered the intervention
beneficial [26], and that the JRVR intervention led to
greater reductions in presenteeism (measured using the
WLQ-25 at 9 month follow-up) compared to the control
intervention [25]. This supported the need for a defini-
tive trial.
Choice of comparators
As in our feasibility trial, the control group will receive a
written work self-help information pack and usual care.
We have chosen a self-help information pack, posted to
participants, as the control intervention because patients
with RA, UIA or PsA often receive little or no work ad-
vice from Rheumatology services [6, 7]. “Usual care”
could include some patients receiving brief work advice
from therapists but many would not. In our feasibility
trial, therapists reported that it was more common for
patients to receive an information booklet on work and
arthritis, although many may not even receive this, if not
referred to occupational therapy. We discussed with
therapists what the control intervention should be: brief
(i.e. about 45 min) work advice; or work information
booklets. The therapists’ consensus was that, once they
had received training in Workwell, they would find it
more personally conflicting to provide only brief work
advice to control participants, as they would now know
how to provide work rehabilitation. Accordingly, their
decision, supported by our patient research partners,
was that they preferred not to have the control partici-
pants referred to them and that the control group
should receive a self-help information pack (which is
also provided to the intervention group). This pack en-
sures all participants receive the same high-quality writ-
ten information. Additionally, this approach has been
used as a control in other JRVR trials [17, 21]. The ther-
apists in our feasibility trial agreed that the pack con-
tained more information within the booklets than the
brief advice that they might provide to employed pa-
tients. Accordingly, they considered control participants
would not be disadvantaged in receiving this pack in-
stead. Indeed, many would be advantaged, as they would
not otherwise receive any work information.
For the WORKWELL trial, we have increased the con-
tent of the information pack (compared to that in the
feasibility study) to include more information on the
Equality Act and practical work self-help solutions and
resources. If referred to occupational therapy during the
WORKWELL trial for other reasons, control participants
continue to receive self-management education, splint-
ing and other interventions as part of “usual care.”
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Therapists were asked not to provide WORKWELL
JRVR to non-trial participants during the trial. This
was to avoid their normal service provision being
changed by the trial as control participants could
then be disadvantaged. Therapists considered this
would not be feasible anyway, as their services are
not normally funded to provide a full work rehabilita-
tion service.
The intervention group will receive usual care plus the
same information pack as the control group plus
WORKWELL. The WORKWELL JRVR intervention is
the same as developed in the feasibility trial [25]. We
chose to test this intervention as systematic review iden-
tified this was effective in the USA, the most pragmatic
intervention available and we have already tested it for
acceptability and feasibility. We chose to deliver WORK-
WELL by therapists working in NHS Rheumatology out-
departments because people with inflammatory arthritis
are usually referred quickly to, and receive ongoing dis-
ease management from, such services, allowing for regu-
lar opportunities to identify patients’ work problems.
Objectives
The primary objective is to assess whether there is a
clinically important difference in work presenteeism
(measured using the Work Limitations Questionnaire–
25: WLQ-25 [27]), in people with RA, UIA or PsA re-
ceiving: WORKWELL JRVR compared to written work
self-help information, in order to assess the work-related
benefits to patients.
The secondary objectives are to:
i. Assess the effectiveness of WORKWELL JRVR
relative to the control intervention on: work activity
limitations, work instability, work productivity,
absenteeism, work status, satisfaction with work
advice/support received, work self-efficacy, health
status and quality of life.
ii. Determine the cost-effectiveness of WORKWELL
JRVR from both an NHS and employer perspective.
iii. Understand the social and structural context in
which the intervention is delivered and to identify
factors which may influence the quality of
implementation, through conducting a process
evaluation.
iv. Investigate contextual factors influencing
participants’ presenteeism.
Trial design
The WORKWELL trial is a definitive, pragmatic, multi-
centre superiority randomised parallel group trial of
WORKWELL JRVR compared to written work self-help
advice in people with RA, UIA or PsA with work in-
stability. Both groups will continue to receive usual care.
Analysis will be on an intention-to-treat basis. Ethical
approval for this study was obtained from the West
Midlands – Solihull Research Ethics Committee (18/
WM/0327). The study protocol was developed using the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) guidelines [28].
Methods
Study setting
Study participants will be recruited from Rheumatology
and Therapy departments in 22 hospitals across 18 NHS
Trusts in England, Wales, and Scotland in the United
Kingdom (UK). Study sites are listed in the Acknowl-
edgements. In the UK, people with RA, UIA and PsA are
predominantly treated in Rheumatology departments in
secondary care and this is where therapists are most
likely to be able to provide JRVR for this client group.
Eligibility criteria
Inclusion criteria
a) Aged ≥18 years.
b) Diagnosed with RA, UIA or PsA by a
Rheumatology Consultant. (UIA is defined as:
persistent synovitis without any other known cause,
but the person does not yet meet all the diagnostic
criteria for RA [29]. Participants can have other
comorbidities.
c) In paid work (full or part-time, self-employed or
regular contractual work) for at least 15 h per week.
d) Not on sick leave or, if on sick leave at screening,
this must be less than 4 weeks (in which case entry
is deferred, and the patient is re-screened on full re-
turn to work).
e) Able to read and understand English.
f) Score ≥ 10 on the RA-Work Instability Scale (RA-
WIS), a measure of mismatch between the person’s
abilities and their job demands. A score of ≥10 is in-
dicative of medium to high risk of work instability
and need for JRVR [30, 31].
g) Able to attend for WORKWELL appointments
h) Able to provide informed consent.
Exclusion criteria
a) On extended sick leave (i.e. > 4 weeks).
b) Planning to retire within the next 12 months and
thus unable to complete follow-up
c) Planning to move out of area within the next 4
months and unable to continue to attend
WORKWELL.
d) Already receiving/ awaiting JRVR services from
other sources e.g. Access to Work or a Vocational
Rehabilitation company.
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e) Employed in the armed forces (which have their
own JRVR service).
Interventions
Control and intervention groups: treatment regimens
Control group The control group will receive usual care
and a written work self-help information pack.
The pack includes a letter encouraging people to work
through a self-help flowchart advising on how to identify
work problems and find solutions. Four work advice
booklets are included, which reference further work re-
sources [32–35].
WORKWELL intervention group This group will re-
ceive usual care plus the same information pack as the
control group plus WORKWELL. Within two working
days of the participant being randomised, the Lancashire
Clinical Trials Unit (CTU) will mail the work self-help
information pack to the participant. This includes a
cover letter informing them they will be contacted
within the next week by a therapist who will arrange the
first WORKWELL appointment as soon as possible,
within a maximum of 4 weeks.
The WORKWELL intervention is a mutually-agreed,
tailored, individualised programme to meet each partici-
pant’s priority work-related needs. It consists of: meet-
ings between the participant and therapist held at
mutually agreed times (early or late in the day to fit
around participants’ work commitments where possible)
and locations (mainly the Therapy department, but also
participant’s home or workplace, if applicable) spread
over two to four months. WORKWELL consists of up to
four × 1-h face-to-face meetings, and a 30-min telephone
review after 6 weeks to check progress. The therapist
can provide treatment in shorter or longer appoint-
ments. If the participant has more complex problems
and/or requires one workplace visit, a further 2 hours is
allowed. The intervention starts with a structured work
interview and job discussion using the UK WES-RC [23,
24]. This is an assessment of the person’s job, roles and
responsibilities in relation to their condition, disease se-
verity and activity limitations and a detailed assessment
of work barriers. This is followed by mutually agreeing
priority work problems, action planning, and a tailored,
individualised programme including self-management at
work, job accommodations, employment rights informa-
tion and other strategies as relevant. The therapist uses
the Work Solutions Manual to identify relevant solu-
tions, as needed. A work site visit is conducted, if this is
identified as relevant to their needs and the participant
and employer agree. The participant’s responsibilities in
liaising with employers are emphasised and role play in-
cluded, as necessary, to enhance confidence requesting
job accommodations. Therapist and participant may also
liaise with UK Government-funded services e.g. Access
to Work and Disability Employment Advisors, and any
occupational health support available in the participant’s
workplace. WORKWELL includes both direct (i.e. with
the participant) and indirect JRVR (i.e. non-contact time
when therapists: use resources to identify solutions for
work problems; liaise with team members, other agen-
cies and employers; complete treatment notes; and travel
time to conduct work site visits). WORKWELL is nor-
mally up to 6.5 h direct and indirect JRVR in total per
participant (see Supplementary Materials 1).
To improve adherence, participants are enabled to write
an action plan at the end of each appointment. Progress in
meeting the plan is reviewed at the beginning of the next
appointment. The plan and progress are recorded in the
WES-RC continuation notes. The participant is reminded
about any elements still to be completed or ongoing. If a
participant does not attend or respond to the therapists
attempts to re-schedule the appointment (four attempts
can be made by telephone and in writing), the therapist
will record this and reason for non-attendance (if known)
in the Treatment Record. In the feasibility trial 25/29
intervention group participants attended [25]. We there-
fore anticipate an 86% adherence rate with attending
WORKWELL although it could be lower.
Concomitant care
Therapists are asked not to provide work rehabilitation
to control group participants whilst they are in the trial
(i.e. during their one-year participation). All participants
continue to receive usual care, i.e. Rheumatology clinic ap-
pointments, prescribed medication and referrals to the
multidisciplinary team, as applicable, for rehabilitation.
Data on participants’ use of concomitant care is collected
via the baseline, six- and 12-month questionnaires.
Criteria for discontinuing or modifying allocated
interventions
The WORKWELL intervention will be delivered by the
WORKWELL Therapist to meet the participant’s indi-
vidual needs, selecting from the range of solutions avail-
able. WORKWELL will be discontinued only if: the
treating therapist identifies a serious adverse event
resulting from WORKWELL; or the participant stops at-
tending. Serious adverse events resulting from WORK-
WELL are not expected due to the low risk associated
with the intervention; none were identified in the feasi-
bility study. If treatment stops, the date and reason will
be recorded by the therapist. It is highly unlikely any
harm will arise from receiving the work self-help infor-
mation pack. Any participant discontinuing WORK-
WELL will remain in the trial for follow-up unless
choosing to withdraw.
Hammond et al. BMC Musculoskeletal Disorders          (2020) 21:607 Page 5 of 20
Therapist training in WORKWELL JRVR
WORKWELL will be delivered by NHS therapists who
specialise in rheumatology and musculoskeletal condi-
tions. Participating therapists will attend a two-day
WORKWELL training course, delivered by expert JRVR
therapists (trainers) and the research team. This will in-
clude: trial background; key study procedures; how to
conduct the WES-RC; case studies; practical workshops;
and self-study materials. The therapists must then
complete a role-play telephone WES-RC with one of the
JRVR trainers, based on a case study, and write an ap-
propriate treatment plan. Therapists will receive mentor
support by telephone and e-mail from one of the JRVR
trainers, including formal feedback on the WES-RC as-
sessment and treatment plan for their second partici-
pant. All therapists are provided with the WORKWELL
Solutions Manual, available in hard copy and online.
The training was further developed from that delivered
in our feasibility study [6]. It was emphasised that ther-
apist should not provide WORKWELL to other patients
or disseminate programme content to other therapists in
order to reduce risk of contamination.
In addition, the research team will conduct site visits
to ensure all Principal Investigators, research facilitator/s
(i.e. nurses or other health care staff employed in the
NHS to assist with recruitment into trials) and therapists
involved understand how to explain the study
appropriately.
Ancillary and post-trial care
Participants are covered by indemnity for negligent harm
resulting from provision of WORKWELL through the
standard NHS Indemnity arrangements. The University
of Salford is the sponsor for the study and has insurance
to cover for non-negligent harm associated with the
protocol. If the trial provides evidence of the effective-
ness of WORKWELL, then control participants will be
informed of this. Participants can request referral from
the Rheumatology to their Occupational Therapy de-
partments for provision of work advice. It will be the de-
cision of participating departments whether they can
provide the full WORKWELL intervention to patients or
whether usual care is provided.
Participant timeline
After giving written, informed consent participants will
complete a baseline questionnaire. Baseline is the date
by which the consent form, trial registration form and
questionnaire are verified as complete. Documents are
normally sent that day by the co-ordinating research
team to the Lancashire CTU, which randomises within
two working days. After randomisation, and within two
working days, all participants are mailed the work self-
help information pack with a cover letter identifying
their group allocation. Within 4 weeks of randomisation,
a WORKWELL appointment will be arranged for those
randomised to the intervention group. Participants in
this group then attend a further one to three appoint-
ments (with optional work site visit) and telephone re-
view over the next four to five months. Most
participants should have completed treatment before the
six-month follow-up. Participants will receive the follow-
up questionnaires at six- and 12-months following the
date of baseline (See Figs. 1 and 2). Following this, ap-
proximately 15 to 20 participants from the intervention
group will be interviewed.
Outcomes
The primary outcome is the Work Limitations
Questionnaire-25 (WLQ-25) at 12 months [27]. Present-
eeism has the greatest impact on costs for people with
RA, making it the most relevant primary outcome. At
the time of trial planning, the Outcome Measures in
Rheumatology (OMERACT) Work Group identified the
WLQ-25 and Work Activity Limitations Scale (WALS)
as the most applicable presenteeism measures [36, 37].
The WLQ-25 has since been identified as having the
strongest psychometric properties [38]. Accordingly, the
trial sample size was calculated using the WLQ-25. Sec-
ondary outcomes include work instability, additional
presenteeism measures, work status, absenteeism and
work self-efficacy, as the focus of the intervention is af-
fecting the work environment and the person’ ability to
meet their job demands. Additionally, we are including:
health outcomes to investigate whether enhancing work
ability impacts on health status; contextual factors which
may influence work ability; and resource use and costs
to measure cost-effectiveness of WORKWELL (Table 1).
Data collection
The baseline questionnaire includes: demographic fac-
tors i.e. age, gender, living situation, ethnicity, educa-
tional qualifications; employment factors, i.e.
employment status, main job title; hours worked, job
features (e.g. working overtime, shift work), organisation
size, work-related support services accessed; and condi-
tion specific factors, i.e. symptom duration, time since
diagnosis. For each of the following outcomes, the
metric will be the final value, and aggregated as means.
The baseline, six- and 12-month follow-up question-
naires include (unless otherwise stated):
Work- related outcome measures
i) The Work Limitations Questionnaire (WLQ-25): a
25-item reliable, valid measure of presenteeism, in-
dicating the amount of time, in the last 2 weeks, a
person was limited in: physical work demands, time
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demands, mental-interpersonal demands and output
demands. The summed score (i.e. of the four sub-
scales) will form the primary outcome measure [27].
Secondary outcomes include:
ii) Presenteeism:
 WLQ-25 sub-scales: the four subscales measuring
physical work demands, time demands, mental inter-
personal demands and output demands from specific
items in the WLQ-25 questionnaire [27].
 The Work Activities Limitations Scale (WALS): a
reliable, valid measure including 12 items assessing
degree of difficulty performing work activities (0 =
no difficulty; 3 = unable to do [40].
The WLQ-25 and WALS will be collected using the
combined WLQ-25 and WALS, from which each can be
calculated, as well as a dual-key scored outcome [41].
Subsequent to the trial starting, this dual-key scored out-
come is now supported by the OMERACT Work Prod-
uctivity Group as the current best available measure of
presenteeism, and a better predictor of work cessation
than the original WLQ-25 [41, 55].
Fig. 1 WORKWELL Trial Flowchart of participants
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 The Work Productivity and Activity Impairment
Questionnaire General Health V2.0 (WPAI:GH): a
reliable, valid measure of extent of absenteeism,
presenteeism, and impairment in daily activities
attributable to general health [42].
iii) Work status: whether in full- or part-time work at
six and 12 months, collected using the Work Tran-
sitions Index [43];
iv) Absenteeism: each month, the number of days
sickness absence attributable to arthritis or other
causes. This is collected by text, e-mail or
telephone.
v) RA-Work Instability Scale (RA-WIS): at 0 and 12
months: reliable, valid measure including 23 true/
false items measuring mismatch between functional
abilities and job demands [30]
vi) Work Self-efficacy: at 0 and 12months: three 0–10
numeric rating scales (NRS) asking about confidence
in: ability to work; ability to manage their health con-
dition at work; and working will not make their
health worse. Additionally, three 0–10 NRS will be
used to measure: motivation; importance and confi-
dence to continue working over the next year.
Health outcome measures
i) SF-12v2 Health Survey: a reliable, valid measure
including 12 items scored as physical and mental
health sub-scales [44].
Fig. 2 SPIRIT Flowchart: Schedule of enrolment, interventions, and assessments
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Table 1 Outcome measures in the WORKWELL trial
Data collection Measurement Method Details 0-Months 6-Months 12-Months
Contextual factors: personal (demographic; disease status)
Age Date of birth ✓
Gender ✓
Ethnic group ✓
Marital status ✓
Living status Alone; or with family/ significant others ✓
Educational status Highest qualification ✓
Time since RA/ IA/
PsA symptom onset
✓
Time since RA/ IA/
PsA diagnosis
✓
Comorbidities Rheumatic Disease Comorbidity
Index [39]
Presence/absence of 11 comorbidities ✓
Job Descriptors a) number of hours worked/week; b) contract
type/ self-employment; c) length of time in
current main job (0 m only).
✓ ✓ ✓
Income status Sole income earner in household ✓
Primary Outcome measure:
Presenteeism The Work Limitations Questionnairea
(WLQ-25) [27]
25 items: percentage time (in last 2/52) limited
in: physical work demands, time demands,
mental-interpersonal demands and output de-
mands (0–4 scale of 0 to 100%).
✓ ✓ ✓
Secondary outcome measures
Presenteeism Work Activities Limitations Scalea
(WALS) [40]
12 items: degree of difficulty in work activities
(0 = no difficulty; 3 = unable to do)
✓ ✓ ✓
Combined WLQ-25 WALSa [41] Combination of above two measures ✓ ✓ ✓
WLQ-25 [27] 4 subscales calculated from relevant items in
the WLQ-25 questionnaire
✓ ✓ ✓
Absenteeism and
Presenteeism
Work Productivity and Activity
Impairment Questionnaire General
Health V2.0 (WPAI-GH) [42]
Last 7 days: time off on sick leave/any other
reason; hours worked; health problems effect
on work productivity and ability to do other
daily activities.
✓ ✓ ✓
Work status Work Transitions Index [43] Whether employed; in full- or part-time work ✓ ✓ ✓
Work instability Work instability scale (RA-WIS) [30] 23 true/false items: degree mismatch between
functional abilities and workplace demands
✓ ✓
Work self-efficacy 0–10-point numeric rating scales (NRS) 0 = not
at all to 10 = very.
3 work self-efficacy items (confidence in work-
ing, managing health condition at work and
work not making condition worse (0–10 NRS)
✓ ✓
Health Outcome measures
Health status SF-12v2 Health Survey [44] 12 items, assessed over the last four weeks,
scored as physical and mental health sub-scales
✓ ✓ ✓
Disease impact Rheumatoid Arthritis Impact of
Disease (RAID) [45]
Composite score from: 7domains of impact of
RA: coping, emotional wellbeing, fatigue,
physical function, sleep, global assessment and
pain
✓ ✓
Disease activity RA Disease Activity Index-5 (RADAI-5)
[46]
Self- reported disease severity in last 6 months;
current joint tenderness and swelling; pain,
general health; hand joint stiffness duration
✓ ✓
Hand/ wrist pain In the last week during moderate activity (e.g.
cooking, housework): 0–10 NRS
✓ ✓
Exploratory outcome measures
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Table 1 Outcome measures in the WORKWELL trial (Continued)
Data collection Measurement Method Details 0-Months 6-Months 12-Months
Number of hours
worked
On average, number of hours contracted to
work and number of hours usually work
✓ ✓ ✓
Change in
occupation or hours
Any change in occupation or number of hours
worked with reason for change
✓ ✓
Work self-efficacy Confidence, motivation and importance of
continuing to work over next year, scored 0–10
✓ ✓
Work advice received Satisfaction with work advice received (0–10
NRS) and what other work advice they received
from where
✓
Economic Evaluation: Use of Resources
Health related
Quality of Life
EuroQol Five Dimensions
questionnaire (EQ-5D-5L) [47]
5-items Scale (Mobility; Self-care; Usual activities;
Pain/Discomfort; Anxiety/Depression; plus 0–100
scale
✓ ✓ ✓
Use of NHS and
Social Care, Local
Authority and Private
Health Services
Your use of hospital in-patient
services
a) Any planned hospital overnight stays in the
last 6 months b) If yes, department, and
number nights
✓ ✓ ✓
Your use of hospital out-patient
appointments
a) Any planned hospital outpatient
appointments lasting 4 h or less in the last 6
months b) If yes, department and number of
appointments
✓ ✓ ✓
Your use of day hospital
appointments
a) Any day or hospital outpatient lasting more
than 4 h but not overnight during the last 6
months b) If yes, department, and number of
appointments
✓ ✓ ✓
Your use of accident and
emergency services
a) Any A&E attendance in the last 6 months b) If
yes, number of visits not leading to hospital
admission c) number of visits admitted into a
hospital as an in-patient from A&E d) reason for
admission
✓ ✓ ✓
Your use of primary and
community-based health services;
Local Authority Social Services; pri-
vate health services
a) Use of primary care services / Local Authority
Social Services (e.g. GP, Practice Nurse, District
Nurse, Counsellor, social worker, occupational
therapist) in the last 6 months b) If yes, number
of visits to each
✓ ✓ ✓
Medication Current medication for RA/IA/PsA; date
medication started
✓ ✓ ✓
Workplace changes Changes to workplace environment Changes made by employer (e.g. specialised
equipment).
✓ ✓ ✓
Contextual factors: environmental factors
Nature of work Job skill level 1–4 (UK Standard
Occupational Classification
(SOC2010)) [48].
Main job title and industry working in ✓
Job responsibilities e.g. overtime, variable hours; and need to travel
for business
✓
Work demands Two items: physical and mental work demands ✓ ✓
Control over work and flexibility
[49]
Four items: control over work schedule, job
flexibility, ability to postpone work tasks and
help from colleagues with work
✓ ✓
Work productivity One item: self-reported work productivity in the
last 6 months
✓ ✓ ✓
Work Transitions The Work Transitions Index (WTI)a
[43].
Includes a) employment status; b) 14 items
assessing: job disruptions due to arthritis c)
sickness absence due to arthritis or other
conditions in the last 6 months; d) change in
occupation or working hours in the last 6
months.
✓ ✓ ✓
Workplace Support The Perceived Workplace Support a 19-item questionnaire, of perceived ✓ ✓
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ii) Rheumatoid Arthritis Impact of Disease scale
(RAID): a valid, reliable measure assessing seven
domains of impact of RA: coping, emotional
wellbeing, fatigue, physical function, sleep, global
assessment and pain [45]. This will be measured at
0 and 12 months.
iii) RA Disease Activity Index-5 (RADAI-5): identifying
disease activity categories based on perceived dis-
ease severity in last 6 months, and current joint ten-
derness and swelling, pain, general health and hand
joint stiffness [46]. This will be measured at 0 and
12months.
iv) Hand/ wrist pain: pain in the last week during
moderate activity (0–10 NRS), measured at 0 and
12months.
Health economic outcome measures
i) Health related quality of life: measured using the
five-level version of the EuroQol (EQ-5D-5L) [47].
The EQ-5D is recommended by the National Insti-
tute of Health and Clinical Excellence (NICE) for
use in the economic evaluation of healthcare
interventions.
ii) Health and work resource use questionnaire: a
bespoke tool for determining the extent of trial
participants’ primary, secondary and private health
care use over the preceding six-month period. The
tool also prompts individuals to recall their use of
medications and any changes made in the work-
place relating to their condition.
We will also collect information on: exploratory out-
comes, which we will compare across randomised
groups, but will not be considered as formal secondary
outcomes and work-related contextual factors to explore
their potential impact on outcomes (listed in Table 1).
Process evaluation
An embedded process evaluation informed by Normal-
isation Process Theory will explore how WORKWELL is
understood, valued, adopted into practice and monitored
by those involved [56]. It will include interviews with
participants, employers, therapists and their line man-
agers, as well as analysis of therapists’ WES-RC assess-
ment and trial treatment records. Additionally, we will
check treatment fidelity through analysis, for each site,
of at least one audio-recording of a participant’s initial
assessment and analysis of that participant’s WES-RC
and trial treatment record. This will investigate whether:
the WES-RC assessment was conducted correctly; and
an applicable treatment plan developed and delivered, in
relation to the recorded problems identified and
Table 1 Outcome measures in the WORKWELL trial (Continued)
Data collection Measurement Method Details 0-Months 6-Months 12-Months
Scale (PWSS) [50] managerial, co-worker and organisational sup-
port (REF)
Work support services Access to occupation health and work support
services
✓ ✓
Work Policies and
Accommodations
The Workplace Accommodations,
Benefits, Policies and Practices Scale
(WABPPS)
[51, 52]
17 items: job accommodations, policies and
workplace practices available, use of and
helpfulness
✓ ✓
Organization Polices Organization size Numbers of employees in company ✓
Contextual Factors: Personal
Personal appraisal Job strain
[53]
One item: stress currently experienced at work ✓ ✓
Work motivation/ importance/self-
efficacy
3 items: motivation, importance and confidence
to continue working (0–10 NRS) (0–10 NRS)
Disclosure
[50]
Disclosure about condition to employer /line
manager
✓ ✓
Job satisfaction Satisfaction with job: 0–10 NRS ✓ ✓
Future job expectations Two items: concerns about health affecting
ability to work in future; and likelihood of
leaving job in the next year due to arthritis
✓ ✓
Work-Life Balance Work-life balance
[54].
Four items: perceived work-life balance taken
from the Work, Health Life Balance Perceptions
Scale
✓ ✓
Notes: a the WLQ-25 and WALS will be collected within the Combined WLQ-25 WALS dual scored measure [41]
Each month, employment status and absenteeism will be collected by the Lancashire Clinical Trials Unit via e-mail or telephone
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recorded. A separate process evaluation protocol will be
prepared.
Sample size
This was calculated using data from the feasibility study.
The minimal clinically important difference for the
WLQ-25 is estimated as 13 points in the summed score
[57]. The standard deviation (SD), pooled across the
intervention and control groups, was 20.64 in the feasi-
bility trial. As the SD might be an under-estimate, the
80% upper one-sided confidence limit of the estimated
SD, i.e. 23.02, was used. Although the WORKWELL trial
is individually, rather than cluster randomised, we are
concerned that the effect of the WORKWELL interven-
tion may vary by therapist (as there is more than one
therapist at 11 of the 22 hospitals in the 18 sites). This
could lead to a clustering effect on outcome. No such ef-
fect is expected in the control intervention. We therefore
performed the sample size calculation using the clsampsi
Stata command [58]. As we do not expect the clustering
effect to be large, the intra-class coefficient (ICC) for the
WORKWELL intervention arm = 0.05 and control arm =
0. To identify a 13-point difference, SD = 23.02, p = 0.05
and 90% power, 90 participants are required in each
group. Allowing for a 25% attrition rate at 12 months
(i.e. non-completion of the WLQ-25 at 12 months due
to no longer working or on long-term sick leave; or non-
return of the 12-month questionnaire) we intend to re-
cruit and randomise 240 participants in equal numbers
to the two groups. We anticipate we may need to obtain
consent from up to 300 patients to achieve 240 partici-
pants at randomisation (as some will not complete and
return their baseline questionnaire, and some may be-
come ineligible prior to randomisation) and 180 partici-
pants with 12-month outcome data.
Recruitment
At each participating site a Principal Investigator (PI)
(senior therapist/consultant rheumatologist) will be
appointed, to be responsible for identification, recruitment,
consent and provision of baseline questionnaires, along
with adherence to the study and treatment protocols, fol-
lowing Good Clinical Practice Guidelines (GCP).
Members of the health care team and therapists at
participating sites will identify adult patients with RA,
UIA or PsA during the patient’s Rheumatology or re-
habilitation appointment. Either a research facilitator or
therapist will then screen (in person or by telephone) pa-
tients for eligibility using the WORKWELL Trial Eligi-
bility Screening Form. (See Fig. 3 for recruitment
procedure). All eligible patients will be provided with a
study explanation and information pack.
If a site is encountering difficulty identifying enough
numbers during clinic appointments, then potential partici-
pants will be identified from medical or therapy records by
members of the health care team. The patient will then be
mailed a study information pack by the research facilitator
or therapist. On return of a WORKWELL Contact Details
Form from the patient indicating interest in the study, the
research facilitator or therapist will then complete
Fig. 3 Recruitment flowchart: participants identified in rheumatology clinic/occupational therapy
Hammond et al. BMC Musculoskeletal Disorders          (2020) 21:607 Page 12 of 20
recruitment and consent procedures by telephone and mail.
(See Fig. 4 for recruitment procedure.)
In some cases, a research facilitator or therapist may
be unable to either screen, explain the study, and/or take
consent in person or by telephone with a patient (e.g.
the patient cannot stay in or return to clinic as they need
to be in work; NHS staff are unable to telephone the pa-
tient in the evening; NHS staff have insufficient time/
are unavailable to complete the activities). In these cases,
following the patient’s written consent for their contact
details to be forwarded to the co-ordinating centre (at
the University of Salford), a member of the research
team will complete these activities.
Consent is completed by the research facilitator, ther-
apist or member of the co-ordinating research team.
Participants are also asked to consent to being contacted
in future to ask about taking part in a longer-term
follow-up for this study, and other associated studies.
The participant information sheet and consent form can
be seen in the Supplementary Materials. Following con-
sent, participants will be provided with a baseline ques-
tionnaire to complete at home and return in a Freepost
envelope to the trial manager. On receipt of the com-
pleted questionnaire, the trial manager will enter their
details into the trial spreadsheet, securely e-mail scanned
copies of the trial registration form, consent form and
baseline questionnaire to the Lancashire CTU and re-
quest that the unblinded CTU staff perform the
randomisation.
Assignment of intervention
Allocation and sequence generation
Participants will be randomly assigned to either the
WORKWELL intervention or control with a 1:1 alloca-
tion as per a computer-generated randomisation sched-
ule. Participants will be stratified by their skill level
group (two strata: Stratum A - Level 1 (elementary occu-
pations) or 2 (Administrative, caring, leisure, sales, cus-
tomer service; process, plant and machinery operatives);
Stratum B - Level 3 (Associated professional and tech-
nical/ skilled trades) or 4 (Professional and manager-
ial) [48], using permutated blocks of random sizes.
Stratified randomisation ensures equal distribution of
job skill levels across the two groups.
Concealment mechanism
Participants will be randomised using ‘Sealed Envelope,’
a secure, online, central randomisation service [59]. The
block sizes or schedule will not be disclosed to the ther-
apists, research facilitators or research co-ordinating
team to ensure concealment. Randomisation will occur
only after the trial manager and CTU confirm a
Fig. 4 Recruitment flowchart: participants identified from records/ clinic and not seen in person
Hammond et al. BMC Musculoskeletal Disorders          (2020) 21:607 Page 13 of 20
participant’s eligibility, consent, trial registration and
that they have completed the baseline questionnaire.
Implementation
Within two working days of notification by the trial
manager, unblinded CTU staff will perform the random-
isation and securely e-mail a referral for either interven-
tion or control to the relevant site. Within two working
days of the participant being randomised, the CTU will
mail the work self-help information pack to the partici-
pant. For those randomised to WORKWELL, the treat-
ing occupational therapist will contact the participant by
telephone, text or e-mail within five working days of re-
ferral to make a mutually convenient appointment to
commence WORKWELL as soon as possible and within
4 weeks of referral.
Blinding
Due to the nature of the intervention it will not be pos-
sible for therapists to be blinded to group allocation.
Therapists are informed not to provide the WORK-
WELL intervention to any other patients. None of the
participating sites normally conduct full work assess-
ments and detailed work provision. To reduce the risk of
contamination of the control group (i.e. therapists pro-
viding control participants with JRVR), WORKWELL
therapists will be informed which participants are in the
control group. They will enter the participant’s details
onto the Control Participant Log within the Trial Ther-
apy site file. Therapists are requested to check with pa-
tients whether they are in the WORKWELL trial and
check this Log before providing any brief work advice to
patients. Participants cannot be blinded to the interven-
tion they receive. However, we will present the study in
the Participant Information Sheet as a trial comparing
two methods of providing work advice, without any sug-
gestion that one is preferable. The study explanation in-
cludes the conflicting evidence from previous trials and
that full JRVR is rare in Rheumatology services. Thus,
patients will be informed that, in either arm, they will re-
ceive more information about managing work problems
than normally available. The trial manager and co-
ordinating research team are not blinded to group
allocation.
Data co-ordination and data entry staff at the CTU re-
sponsible for baseline and follow-up questionnaire man-
agement and contacting participants to obtain any
missing data at follow-ups, will be blinded to group allo-
cation. The CTU trial manager, data manager and infor-
mation systems team will be unblinded. The Trial
Statistician will initially conduct the analyses blinded to
group allocation, ignoring the therapist clustering effects
as these cannot be accounted for without knowing group
allocation. After the results under blinding have been
shared, the Trial Statistician will become unblinded and
the analyses will be re-run accounting for therapist ef-
fects. Adjusting for therapist effects will only impact the
precision of estimates, rather than their magnitude. The
health economist will be not be blinded as the costs of
WORKWELL will be included in the analysis.
Emergency unblinding
Not applicable as serious adverse events are not known
to occur in clinical practice.
Data collection methods
Outcomes will be collected via self-reported question-
naires at baseline (i.e. prior to randomisation) and follow-
up after six and 12months. At six-month follow-up, par-
ticipants will normally have completed their intervention
(which normally extends between three to five months
and should be started within 4 weeks of randomisation)
and have been progressively implementing job accommo-
dations and self-management at work. Data collection is
via postal questionnaire with an on-line option available at
six and 12months, provided via e-mail with a weblink
(using Research Electronic Data Capture (REDCap) [60].
The trial manager (baseline) and CTU (six and 12months)
will monitor return of questionnaires.
• At 2 weeks after questionnaire provision/mailing, if
the questionnaire is not yet returned, the trial manager
[baseline questionnaire] or CTU [six- or 12-month ques-
tionnaire] will text/e-mail/ telephone (as applicable) to
remind the participant to return their questionnaire.
• At 3 weeks after questionnaire provision/mailing, if
the questionnaire is not yet returned, the trial manager
[baseline questionnaire] or CTU [six- or 12-month ques-
tionnaire] will mail a reminder letter and a further copy
of the relevant questionnaire (with Freepost envelope).
• If the six- or 12-month questionnaire are not
returned by seven and 13months, respectively, the
CTU will then telephone the participant to obtain a
minimal data set. This will include at least the primary
outcome measure (in the form of the WLQ-25 – WALS
combined measure). The following key outcomes will
also be collected if possible: job status (WTI part 1, if
currently on sick leave, and date of stopping/changing
job, if applicable; the WPAI, EQ-5D-5L; thereafter, the
Work Transitions Index (WTI) parts 2,3 and 4, health
resource use, work-related questions, and the SF-12. At
12 months, the RA-WIS will also be collected. If the
CTU are unable to obtain this data, this will be recorded
in the Trial Database and data entered as missing.
Data management and confidentiality
Data validation
Data management personnel will validate each question-
naire prior to data entry, with self-evident errors
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corrected, and recorded. The trial manager or CTU trial
administrators will contact the participant for clarifica-
tion if required.
Data entry and coding
Data received as hard copy will be entered into the trial
database by the CTU data entry personnel. Data entered
online will be automatically entered into the trial data-
base. For every 50 questionnaires entered, data entry will
be verified by batch sampling a minimum of 10% of case
report forms and verifying against the database entries.
A record of errors will be recorded together with actions
and resolutions. The type and number of errors found
will inform the decision about increasing the verification
scope and frequency, up to full data set verification. A
Data Management Plan will be approved by the Trial
Management Group (TMG) prior to implementation.
Confidentiality and data storage
Information about study participants will be kept confi-
dential and managed according to the requirements of
the Data Protection Act, NHS Caldicott Guardian, the
Research Governance Framework for Health & Social
Care, Ethics Committee Approval and University of Sal-
ford Research Governance Procedures. All study-related
information will be stored securely at the University of
Salford and Lancashire CTU. Data on central servers at
either location is stored in password-protected restricted
access folders only accessible to the relevant research
teams at those sites. The REDCap secure web applica-
tion for online questionnaire collection meets the re-
quirements of internationally recognised International
Council for Harmonisation of Technical Requirements
for Pharmaceuticals for Human Use (ICH) Good Clinical
Practice, Federal Drug Agency 21 Code of Federal Regu-
lations Part 11 and the European Union Clinical Trials
Directive. Data hosting storage exceeds International Or-
ganisation for Standardisation 27,001 Information Secur-
ity Management requirements. All data collection,
process, and administrative forms will be identified by a
coded Patient Screening Number (PSN) or Participant
Identification Number (PIN). Patient-identifiable data
will be securely stored separately from data identified by
PSN or PIN. Original baseline questionnaires, partici-
pant documents, treatment and interview audio-
recordings and transcriptions will be securely stored at
the University of Salford. Any hard copy six- and 12-
month questionnaires will be stored at the Lancashire
CTU until transferred to the University of Salford at the
end of the study. Interview recordings will be deleted
following transcription and analysis. Original data and
records will be archived for 6 years at the Centre for
Health Sciences Research, University of Salford.
Data transfer from the University of Salford to CTU
The trial manager at the University of Salford will ensure
copies of all completed baseline questionnaires are pro-
vided, in a timely and secure manner (i.e. scanned and
sent by e-mail using encrypted PDF), to the CTU for
data entry.
Data access
The CTU Principal Clinical Trials Manager and Data
Manager will oversee intra-study data sharing, with in-
put from the Trial Statistician. To ensure confidentiality,
data dispersed to the Supervising and Trial Statisticians,
health economist, and contextual factors team will be
blinded of any identifying participant information. Fol-
lowing analysis, the Chief Investigator will receive a copy
of the final cleaned raw and final datasets and Stata code
for the coding of data and analysis. The members of the
Process Evaluation team will also have access to the
pseudo-anonymised interview data, interview and treat-
ment audio-recordings, WORKWELL WES-RCs and
Treatment Record Forms.
Statistical methods
Primary effectiveness analyses will follow a pre-specified
Statistical Analysis Plan (approved by the Trial Steering
Committee (TSC) and available on request) and will in-
clude the intention to treat population. Data will be
summarised using means, medians or proportions as ap-
plicable. The primary analysis will use mixed effects lin-
ear regression to estimate the effect of group allocation
on WLQ-25 summed index scores, controlling for the
stratification variable in the randomisation process (skill
level group) and the baseline value of the WLQ-25 (both
fixed effects) and therapist (random effect); the six-
month and 12-month outcomes will be analysed in a
single model with an interaction term between time
point (six or 12 months) and randomised group to deter-
mine the treatment effect at both time points separately.
Secondary effectiveness analysis will repeat the primary
analysis method for all other outcomes, using appropri-
ate generalised linear mixed modelling methods (i.e.
mixed effects linear, logistic or ordinal logistic regres-
sion) including six- and 12-month outcomes as available,
controlling for the stratification variable, baseline value
of the specific measure and therapist effect. The inter-
action between time point and randomised group will
not be included for outcomes measured only at 12
months. Sensitivity analyses will include the analysis of
the primary outcome measure excluding anyone allo-
cated to the intervention who did not attend WORK-
WELL and anyone allocated to control but did receive
WORKWELL (the per protocol population). We do not
anticipate undertaking sensitivity analyses on the basis
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of missing data unless there is a great deal and/or large
imbalance in missingness between the two trial groups.
We will also explore the effects of contextual effects
on outcomes via sub-group analyses. This will be an ex-
ploratory analysis for hypothesis generation. Each sub-
group analysis will be specified in advance of starting
analysis, with a theoretical justification for its inclusion.
Analysis will be based on tests of interaction between
group and contextual factors, as part of regression
models. Interpretation will not over-emphasise any stat-
istical or non-statistical significance at the traditional 5%
level given the likely lack of power, multiple sub-group
investigations and expectation that any sub-group effects
will not be substantial. The contextual factors analysis
will be fully described in the Statistical Analysis Plan.
Economic evaluation
A cost-effectiveness analysis (CEA) approach will be
used in the economic evaluation. The base case analysis
will be conducted in line with the NICE Reference Case
[61]. The costs and outcomes of WORKWELL will be
compared to those associated with the provision of usual
care plus the information pack. Additional economic
analyses will consider alternative outcomes measures
and perspectives (see Economic analysis section below).
Costs
Costs to be included in the analysis will reflect those in-
curred by the NHS in terms of providing care in the
control arm and the intervention arm along with any
use of NHS services over the one-year time horizon of
the CEA. Unit costs, identified from relevant sources
(e.g. Department of Health reference costs), will be at-
tached to the collated resource use data to provide over-
all costs for each arm of the study.
Outcomes
In the base case analysis, Quality-Adjusted Life Years
(QALYs) will be generated for each arm of the trial
using the EQ-5D-5L scores mapped onto EQ-5D-3L
utility values as recommended by NICE [62]. The SF-
12v2 health status measure will be used to generate
QALYs in an additional CEA. Further analyses will em-
ploy the WLQ-25 and the WPAI as outcome measures
for CEAs (see Economic analysis section below).
Economic analysis
Net costs and outcomes for each arm of the trial, adjusted
for baseline characteristics, will be estimated in regression
models. Using an NHS perspective in the base case CEA,
an incremental cost-effectiveness ratio (ICER) will be calcu-
lated to reflect the cost per unit difference in QALYs asso-
ciated with WORKWELL compared to usual care plus
information pack provision. Bootstrapping – where
multiple ICERs are generated through the resampling of
trial data – will be used to characterise uncertainty in the
combined cost and outcomes data. Cost effectiveness ac-
ceptability curves, populated with bootstrapped data, will
be used to illustrate the probability that WORKWELL is
cost-effective given the NICE-recommended threshold of
acceptability [61].
Additional scenario analyses will comprise:
 a CEA conducted in line with the base case analysis
but using the SF-12 to generate QALYs; previous
work has indicated that this tool is particularly ap-
propriate for the economic evaluation of work-based
interventions
 a CEA in which the ICER represents the cost to
employers for reduced presenteeism as measured by
the WLQ-25
 a CEA in which the ICER represents the cost to
employers for reduced presenteeism as measured by
the WPAI
 a CEA in which the ICER represents the cost to
employers for QALY gains and where levels of
presenteeism, as measured by the WLQ-25, are
translated into costs using the human capital
approach
Data monitoring
The trial will not have a separate Data Monitoring Com-
mittee, as the safety risks associated with this study are
very low. Consequently, there are no stopping rules for
safety. The trial will be overseen by a TSC, which will
perform this function.
Harms
There is minimal risk associated with the intervention.
Any adverse event considered by the occupational ther-
apist to be resulting from participation in the trial will
be recorded by the occupational therapist on the
WORKWELL Treatment Record Form during treatment
sessions. This is completed by the six-week review and a
copy returned to the CTU Data Manager. If a participant
notifies the therapist of any other adverse events after
treatment is completed, then the therapist will e-mail
the CTU Data Manager, who will record this addition-
ally on the participant’s WORKWELL Treatment Record
form.
Auditing
The Trial Manager or Chief Investigator will conduct at
least one on-site monitoring visit per year over the
course of the study to all clinical sites to educate, sup-
port and solve problems. A site file checklist will be used
at the visit to ensure the site file is up to date. The trial
manager or chief investigator research team will
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complete the checklist and arrange for any missing doc-
uments to be added. There will also be remote monitor-
ing, by the CTU and Trial Manager, of quality of source
documentation, including consent form completion, ad-
verse event reporting, and deviations from the protocol.
The Chief Investigator will permit study-related moni-
toring, audits and inspections by the Ethics Committee,
lead Research and Development department, the Univer-
sity and any NHS Trust Research Governance Managers
requiring this. The study will be monitored in accord-
ance with NHS and University Research Governance
procedures. The Chief Investigator will ensure that any
regulatory authority is given access to all study-related
documents and study related facilities. Principal investi-
gators will be asked to audit their site files at the begin-
ning and end of the study using a checklist provided by
the University of Salford co-ordinating research centre
and to allow study-related monitoring, audits and in-
spections as above.
Composition roles and responsibilities of: the co-
ordinating centres, trial management group (TMG) and
TSC and data analysis team
Management of the trial is joint between the Centre for
Health Sciences Research, University of Salford (Ham-
mond, Ching and Parker) and Lancashire CTU (For-
shaw). The TMG (consisting of the authors and CTU
trial staff) will approve documentation, study protocol
procedures, advise on ethics application, monitor trial
progress by reviewing the trial progress reports, any
problems arising, be advised of any Serious Adverse
Events, review findings and plan dissemination. The
TMG will meet at three to four monthly intervals and
receive reports of trial progress. Teleconferences and ad-
hoc meetings will be held during the study if issues arise
requiring discussion.
The TSC consists of both independent and non-
independent members (approved by Versus Arthritis).
The TSC will meet four times, act as the Data Monitor-
ing Committee (DMC) and provide trial oversight and
data monitoring. The TSC will meet to approve the
protocol, advice on procedures and progress, data moni-
toring and review findings and monitor trial progress by
reviewing the trial progress reports. No interim analyses
are planned.
Protocol amendments
Any subsequent modifications to the protocol which may
impact on the conduct of the study, potential benefit to the
patient or may affect patient safety, will require a formal
protocol amendment, agreed by TMG and TSC members,
and approved by the approving NRES Ethics Committee
prior to implementation and notification to sites.
Dissemination and author eligibility
The full trial protocol will be available via the University
of Salford Institutional Repository on trial completion.
Topics suggested for presentation or publication will be
circulated to the TMG. Lead authorship and author eli-
gibility for articles will be agreed by the TMG. Findings
will be submitted to rheumatology, rehabilitation and
trial methodology conferences and journals, as relevant.
A summary of findings will be provided to relevant
health professional and arthritis patient organizations,
requesting these are included in websites and newslet-
ters. We will provide a summary of the findings to trial
participants via a newsletter and the trial website. If suc-
cessful, we will also provide training materials and infor-
mation resources for therapists in delivery of
WORKWELL and disseminate these as above and will
make these available online.
Studies within a trial (SWAT)
In addition to the main WORKWELL trial, one SWAT
is being conducted.
Pre-notification letter/email sub-study
This SWAT will use a randomised controlled trial, em-
bedded within WORKWELL, to test a pre-notification
communication sent 2 weeks before participants are due
to be sent their 6-month follow-up questionnaire against
a control of no pre-notification. The communication will
take the form of a letter for participants who opt to
complete questionnaires postally and an email for those
who opt to complete electronically. The text in the pre-
notification communication has been theory-informed.
The reminder letter (or email) will be personalised to in-
clude the (typed) name of the participant because there
is some evidence that personalising may improve re-
sponse rates in surveys. Randomisation will be stratified
by WORKWELL trial arm (WORKWELL intervention;
control) and planned method of questionnaire comple-
tion (hard copy; online).
The primary outcome is a valid response (i.e. usable out-
come data) for the WLQ-25 total score obtained by any
means, no more than 56 days after the scheduled 6-month
follow-up time-point. The secondary outcomes are: valid
response for WORKWELL trial primary outcome (yes/no)
without reminder; number of reminders sent; time to re-
sponse [or ceasing follow-up] (days); costs per participant
retained. As is usual with a SWAT, no formal power cal-
culation was undertaken, as the sample size will be con-
strained by the number of participants sent a 6-month
questionnaire. Binary data will be analysed using logistic
regression and time-to-response by a Cox proportional
hazards model. All models will adjust for stratification fac-
tors. We will present a crude analysis of the ratio of the
estimated between-groups difference in costs, divided by
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the corresponding difference in proportions providing
valid responses for the WLQ-25.
Discussion
This protocol describes a definitive, pragmatic, multi-
centre superiority randomised parallel group trial, which
aims to determine the effectiveness and cost-effectiveness
of job retention vocational rehabilitation for employed
people with inflammatory arthritis. The results of this trial
will inform rheumatology teams, NHS managers and ser-
vice commissioners about how to optimise JRVR for
people with inflammatory arthritis, and about the re-
sources needed to achieve this and considerations for
informing its uptake and use in clinical practice (imple-
mentation). We will develop online resources for health
professionals to support delivery of WORKWELL JRVR, if
successful. These resources will be available to support
education of future health professionals and be modified
to be available for use by people with arthritis. The results
will be published in a variety of media with different target
audiences, when available.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12891-020-03619-1.
Additional file 1. WORKWELL Trial: contents of the: Work Self-help Infor-
mation Pack; WORKWELL Job Retention Vocational Rehabilitation inter-
vention; Participant Information Sheet and Consent Form.
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